Evidence map›Paper›PMID 31986261›Full record

ArticleLancet (London, England)2020

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.

Jasper Fuk-Woo Chan, Shuofeng Yuan, Kin-Hang Kok, Kelvin Kai-Wang To, Hin Chu, Jin Yang, Fanfan Xing, Jieling Liu, Cyril Chik-Yan Yip, Rosana Wing-Shan Poon and 11 more

20 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 20 registered trials, which are not on this map. Cited by 4,235 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4,235citing papers in PubMed, 4 pooled it
231.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04251871 naunknown statusnot on this map

Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial

TypeinterventionalSponsorBeijing 302 HospitalRan2020 to 2021Enrolled150ConditionsPneumonia Caused by Human Coronavirus (Disorder)ArmsConventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules, Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)
NCT04349592 nacompletednot on this map

Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

TypeinterventionalSponsorHamad Medical CorporationRan2020 to 2020Enrolled456ConditionsCovid19ArmsHydroxychloroquine, Azithromycin, Placebo Tablet, Placebo capsules
NCT04352803 phase1unknown statusnot on this map

IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)

TypeinterventionalSponsorRegeneris MedicalRan2020 to 2026Enrolled20ConditionsCovid-19 Pneumonia, Cyotokine StormArmsAutologous Adipose MSC's
NCT04365725 completednot on this map

Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.

TypeobservationalSponsorAssistance Publique - Hôpitaux de ParisRan2020 to 2020Enrolled84ConditionsCOVID-19ArmsRemdesivir
NCT04366921 unknown statusnot on this map

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO

TypeobservationalSponsorMaastricht University Medical CenterRan2020 to 2022Enrolled150ConditionsCOVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia
NCT04387799 completednot on this map

Major Determinants of COVID-19 Associated Pneumonia

TypeobservationalSponsorCatholic University of the Sacred HeartRan2020 to 2020Enrolled520ConditionsPneumonia, Viral, Pneumonia, Bacterial, Coronavirus Infection, Obstructive Lung DiseaseArmsSerology for Covid-19
NCT04390269 unknown statusnot on this map

Various Molecular Markers With Predictive and Prognostic Significance in COVID-19 Outcome

TypeobservationalSponsorMansoura UniversityRan2020 to 2022Enrolled200ConditionsGenetic Predisposition to Disease
NCT04393636 nacompletednot on this map

Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)

TypeinterventionalSponsorAcademisch Ziekenhuis MaastrichtRan2020 to 2024Enrolled394ConditionsCardiovascular Diseases, Cardiovascular Risk FactorArmsDigital cardiac Counseling
NCT04420260 nacompletednot on this mapstarted 2021, after this paper: background citation

Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

TypeinterventionalSponsorUnidad de Investigación Genética MolecularRan2021 to 2021Enrolled152ConditionsCOVIDArmsGroup A: oropharygeal spray and immunostimulant emulsion, Group D:Placebo oropharyngeal spray + Placebo taken PO
NCT04430023 completednot on this map

Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia in Intensive Care Unit- a Retrospective, Observational Study in Istanbul, Turkey

TypeobservationalSponsorSisli Hamidiye Etfal Training and Research HospitalRan2020 to 2020Enrolled150ConditionsCorona Virus Infection, Pneumonia, Acute Respiratory FailureArmsepidemiological and demographic characteristics
NCT04438837 naunknown statusnot on this map

Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers: A Randomized-Controlled Trial

TypeinterventionalSponsorRambam Health Care CampusRan2020 to 2022Enrolled582ConditionsCoronavirus Disease 2019 (COVID-19), Post-Exposure ProphylaxisArmsHydroxychloroquine
NCT04457349 nacompletednot on this map

Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?

TypeinterventionalSponsorAlexandria UniversityRan2020 to 2021Enrolled10ConditionsCOVID 19ArmsTherapeutic Plasma Exchange (TPE)
NCT04461340 phase2unknown statusnot on this map

Efficacy and Safety of Sirolimus for Treating COVID-19 Infection

TypeinterventionalSponsorAlexandria UniversityRan2020 to 2020Enrolled40ConditionsCOVID 19ArmsSirolimus
NCT04647695 phase2unknown statusnot on this map

An Open-label Randomized Controlled Trial on Interferon β-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection

TypeinterventionalSponsorThe University of Hong KongRan2020 to 2021Enrolled100ConditionsCovid19ArmsInterferon beta-1b, Remdesivir
NCT04649944 unknown statusnot on this mapstarted 2021, after this paper: background citation

Assessment of the Serological Profile of Children and Adolescents Between 4 and 16 Years of Age Cohabiting With at Least One Family Member Who Tested Positive to COVID-19: an Observational Study

TypeobservationalSponsorUniversity of MilanRan2021 to 2021Enrolled40ConditionsCovid19ArmsSerological test and phone interview
NCT04657406 availablenot on this map

Expanded Access to Zofin for the Treatment of Patients With Mild to Moderate COVID-19 Due to SARS-Cov-2 for Outpatient and Inpatient Population

Typeexpanded_accessSponsorZEO ScientifiX, Inc.ConditionsCovid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress SyndromeArmsZofin
NCT04845880 nacompletednot on this map

Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital

TypeinterventionalSponsorBaskent UniversityRan2020 to 2021Enrolled182ConditionsSARS COV-2 IgG Levels on Health WorkersArmsSpike protein (S) or the nucleocapsid (N) of SARS-CoV-2
NCT05205746 phase2completednot on this mapstarted 2021, after this paper: background citation

Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2021 to 2023Enrolled158ConditionsSARS CoV 2 InfectionArmsRecombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo
NCT05572853 completednot on this mapstarted 2021, after this paper: background citation

Analysis of Electrical Activity of Respiratory Muscles in Patients Undergoing Oxygen Therapy With COVID-19: Cross-sectional Study

TypeobservationalSponsorUniversity of PernambucoRan2021 to 2023Enrolled74ConditionsCOVID-19 Respiratory Infection
NCT05710783 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation

Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2

TypeinterventionalSponsorLaboratorio Avi-Mex, S.A. de C.V.Ran2022 to 2023Enrolled4,065ConditionsSARS-CoV-2 InfectionArmsAVX-COVID/12, ChAdOx-1-S[recombinant]
3 · Its place in the literature

Who cites it

4,235 citing papers in PubMed, 4 syntheses or guidelines pooled it, 9,576 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Minimizing Societal Cost of Epidemics: Optimal Catastrophe Insurance Compensation Allocation.Risk analysis : an official publication of the Society for Risk Analysis · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4,175 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 2 countries.

Jasper Fuk-Woo ChanState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Shuofeng YuanState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Kin-Hang KokState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Kelvin Kai-Wang ToState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Hin ChuState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Jin YangDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Fanfan XingDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Jieling LiuDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Cyril Chik-Yan YipState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Rosana Wing-Shan PoonState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Hoi-Wah TsoiState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Simon Kam-Fai LoDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Kwok-Hung ChanState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Vincent Kwok-Man PoonState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Wan-Mui ChanState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Jonathan Daniel IpState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Jian-Piao CaiState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Vincent Chi-Chung ChengState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Honglin ChenState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China; Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Christopher Kim-Ming HuiDepartment of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
Kwok-Yung YuenDepartment of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China. Electronic address: kyyuen@hku.hk.
University of Hong Kong · HKUniversity of Hong Kong - Shenzhen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn ongoing outbreak of pneumonia associated with a novel coronavirus was reported in Wuhan city, Hubei province, China. Affected patients were geographically linked with a local wet market as a potential source. No data on person-to-person or nosocomial transmission have been published to date.

methodsIn this study, we report the epidemiological, clinical, laboratory, radiological, and microbiological findings of five patients in a family cluster who presented with unexplained pneumonia after returning to Shenzhen, Guangdong province, China, after a visit to Wuhan, and an additional family member who did not travel to Wuhan. Phylogenetic analysis of genetic sequences from these patients were done.

findingsFrom Jan 10, 2020, we enrolled a family of six patients who travelled to Wuhan from Shenzhen between Dec 29, 2019 and Jan 4, 2020. Of six family members who travelled to Wuhan, five were identified as infected with the novel coronavirus. Additionally, one family member, who did not travel to Wuhan, became infected with the virus after several days of contact with four of the family members. None of the family members had contacts with Wuhan markets or animals, although two had visited a Wuhan hospital. Five family members (aged 36-66 years) presented with fever, upper or lower respiratory tract symptoms, or diarrhoea, or a combination of these 3-6 days after exposure. They presented to our hospital (The University of Hong Kong-Shenzhen Hospital, Shenzhen) 6-10 days after symptom onset. They and one asymptomatic child (aged 10 years) had radiological ground-glass lung opacities. Older patients (aged >60 years) had more systemic symptoms, extensive radiological ground-glass lung changes, lymphopenia, thrombocytopenia, and increased C-reactive protein and lactate dehydrogenase levels. The nasopharyngeal or throat swabs of these six patients were negative for known respiratory microbes by point-of-care multiplex RT-PCR, but five patients (four adults and the child) were RT-PCR positive for genes encoding the internal RNA-dependent RNA polymerase and surface Spike protein of this novel coronavirus, which were confirmed by Sanger sequencing. Phylogenetic analysis of these five patients' RT-PCR amplicons and two full genomes by next-generation sequencing showed that this is a novel coronavirus, which is closest to the bat severe acute respiatory syndrome (SARS)-related coronaviruses found in Chinese horseshoe bats.

interpretationOur findings are consistent with person-to-person transmission of this novel coronavirus in hospital and family settings, and the reports of infected travellers in other geographical regions.

fundingThe Shaw Foundation Hong Kong, Michael Seak-Kan Tong, Respiratory Viral Research Foundation Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited, Marina Man-Wai Lee, the Hong Kong Hainan Commercial Association South China Microbiology Research Fund, Sanming Project of Medicine (Shenzhen), and High Level-Hospital Program (Guangdong Health Commission).

Indexed as

AdultAgedBetacoronavirusChinaClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingFamily HealthGenome, ViralHumansMiddle AgedPhylogenyPneumonia, ViralRadiography, ThoracicSARS-CoV-2

Identifiers

PMID31986261
PMCPMC7159286
OpenAlexW3002539152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 14 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.